Updates are available Correction dated 2021-12-21

Article History

First Online: 29 June 2019

Change Date: 21 December 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40256-021-00517-2

Compliance with Ethical Standards

:

: Nicholas Moore has received fees from Bayer for training unrelated to this paper. Yves Cottin has received consulting fees from Bayer, Servier, Astra-Zeneca, Boehringer and Vifor Pharma. Patrick Mismetti has received consulting fees from Bristol-Myers Squibb, Pfizer and Bayer. Jacques Bénichou has no conflicts of interest. Patrick Blin, Caroline Dureau-Pournin, Abdelilah Abouelfath, Regis Lassalle and Cécile Droz are employees of ADERA, the non-profit organization that provides human resources for Bordeaux PharmacoEpi. Their salaries derive from the various studies that are commissioned to Bordeaux PharmacoEpi.

: This study was required by the national healthcare authorities as a post-authorization commitment by Boehringer Ingelheim, which markets dabigatran. It was funded by an unrestricted grant from Boehringer Ingelheim. The company had an observer role and had no part in study design, implementation or analysis, the decision to publish this paper or its content. Bayer has also funded a parallel study on the same drugs under the same circumstances.

: This study was authorized by the National Commission on Informatics and Liberties (CNIL) on 22 October 2015 under number 1858904. It was registered with the European Post-Authorisation Study (EUPAS) registry as EUPAS13017 () and in Clinicaltrials.gov as NCT02785354.